NOVA itself is an innovation. As the first decentralized drug screening platform we had a lot of firsts in our nearly first year. From discovering blindspots in SOTA models to building multimillion libraries of novel synthesizable molecules (including ones with a high similarity to patented drugs), we pushed the boundary of AI drug discovery. Our year in review article pinned in our profile goes through more highlights. We’re currently in the process of hit picking molecules for synthesis and wet lab testing. Also, adding a snippet from our conversation today with our partner @Yalotein on the final stages of launching nanobodies. Team is hard at work. More updates coming soon!

Metanova Labs x Yalotein Biotech NOVA next step: nanobodies and decentralized R&D @metanova_labs is pleased to announce the signing of a MOU with Shanghai-based @Yalotein this collaboration will accelerate our roadmap and mark our entry into biological therapeutics. it extends our capabilities beyond virtual small-molecule screening toward a decentralized multi-modal, end-to-end pipeline. strategic inflection point: - unlocking biological modality: we're moving beyond small molecules. nanobodies are a powerful new class of drugs, and this makes them the first biological modality we are adding to NOVA. - closing the loop with wet lab tests: we're solving the critical gap between virtual predictions and real-world validation. @Yalotein will advance 50 nanobody candidates identified by NOVA into in-vitro testing, transforming #Bittensor #SN68 from a predictive tool into the first step of a tangible drug discovery pipeline. Yalotein Biotech focuses on AI-driven development of macromolecular therapeutics. they use advanced AI and data intelligence to accelerate antibody discovery, spanning the entire process from the atomic to the knowledge level. by integrating bioinformatics with AI, they deliver smarter, faster solutions for designing multispecific antibodies and bioconjugates. this partnership is a significant step toward operationalizing our vision of building a truly decentralized pipeline for medical innovation. #drugdiscovery #antibodies #biotech #desci